Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1 By Ogkologos - July 1, 2025 496 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KOMET study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR EMA Recommends Granting a Conditional Marketing Authorisation for Dostarlimab February 26, 2021 Snowboarder Kimmy Fasani Diagnosed with Breast Cancer Nine Months After Son’s... December 11, 2021 Talk Cancer: How to have conversations that could save lives April 13, 2021 Medical Cannabis Formulation May Be Capable of Killing Breast Cancer Cells,... May 21, 2021 Load more HOT NEWS Exploring Coping Resources to Help with Physical, Practical, and Emotional Challenges... Triplet Therapy with ADT, Docetaxel and Abiraterone Plus Prednisone Improves Survival... Alex Trebek Has Completed Chemo And Will Be Back For The... Bullies Make Fun Of Little Girl Over Cancer Scars, Her Mom...
